Skip to content

Bupivacaine liposomes versus standard Bupivacaine in patients with herpes zoster associated pain: A retrospective analysis

Bupivacaine liposomes versus standard Bupivacaine in patients with herpes zoster associated pain: A retrospective analysis

Status
Active, not recruiting
Phases
Phase 4
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500104193
Enrollment
Unknown
Registered
2025-06-12
Start date
2025-06-15
Completion date
Unknown
Last updated
2025-06-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Herpes zoster neuralgia, presented as postherpetic neuralgia

Interventions

Control group (Pulsed radiofrequency combined with Bupivacaine):None
Bupivacaine liposomes group (Pulsed radiofrequency combined with Bupivacaine liposomes):None

Sponsors

Ningbo Medical Centre Lihuili Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
50 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. ZAP was diagnosed according to the Consensus of Chinese Experts on herpes zoster Diagnosis and Treatment, and the medical records were complete; 2. VAS score > 3; 3. Patients with shingles on the neck, chest, and lumbar;

Exclusion criteria

Exclusion criteria: 1. Long term use of hormones; 2. Injection site infection; 3. Abnormal coagulation function; 4. Liver and kidney dysfunction; 5. Pain area accompanied by spinal tumors, fractures, and disc herniation;

Design outcomes

Primary

MeasureTime frame
vas score;

Secondary

MeasureTime frame
Use of postoperative analgesics tramadol, gabapentin, or pregabalin;Daily living ability rating scale;Adverse event rate;incidence of PHN;

Countries

China

Contacts

Public Contactyingying lou

Ningbo Medical Centre Lihuili Hospital

605570569@qq.com+86 178 5743 6857

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026